Návratnost aktiv společnosti Aerie Pharmaceuticals Inc
Jaká je hodnota metriky Návratnost aktiv společnosti Aerie Pharmaceuticals Inc?
Hodnota metriky Návratnost aktiv společnosti Aerie Pharmaceuticals Inc je -9.21%
Jaká je definice metriky Návratnost aktiv?
Návratnost aktiv (Return on assets - ROA) je rentabilita aktiv. Vypočítá se vydělením celkového příjmu průměrem celkových aktiv.
The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.
Návratnost aktiv společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Aerie Pharmaceuticals Inc
Čemu se věnuje společnost Aerie Pharmaceuticals Inc?
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Firmy s metrikou návratnost aktiv podobnou společnosti Aerie Pharmaceuticals Inc
- Hodnota metriky Návratnost aktiv společnosti ModivCare je -9.22%
- Hodnota metriky Návratnost aktiv společnosti NexGen Ltd je -9.22%
- Hodnota metriky Návratnost aktiv společnosti QuinStreet Inc je -9.22%
- Hodnota metriky Návratnost aktiv společnosti Winfull je -9.22%
- Hodnota metriky Návratnost aktiv společnosti Sri Adhikari Brothers Television Network je -9.21%
- Hodnota metriky Návratnost aktiv společnosti QMC Quantum Minerals Corp je -9.21%
- Hodnota metriky Návratnost aktiv společnosti Aerie Pharmaceuticals Inc je -9.21%
- Hodnota metriky Návratnost aktiv společnosti Tree House Education & Accessories je -9.20%
- Hodnota metriky Návratnost aktiv společnosti Star Equity je -9.20%
- Hodnota metriky Návratnost aktiv společnosti eSun je -9.18%
- Hodnota metriky Návratnost aktiv společnosti Xinji Shaxi Co., Ltd je -9.18%
- Hodnota metriky Návratnost aktiv společnosti BCM Resources je -9.18%
- Hodnota metriky Návratnost aktiv společnosti Arbor Metals je -9.18%